Feature | March 06, 2013

The National Average for D2B Times

A recent review of data from the CathPCI Registry

A recent review of data from the CathPCI Registry, part of the American College of Cardiology’s (ACC) National Cardiovascular Data Registry (NCDR), offers some insight into average, real-world D2B times.[1] For STEMI patients who arrived at an angioplasty-capable hospital, the average time from hospital arrival to treatment was 64.5 minutes. For patients requiring transfer to another hospital, the average time from arrival at the first hospital to treatment was 121 minutes.  

The ACC 2013 STEMI guidelines estimated that almost 90 percent of patients presenting to a hospital with PCI capability and without a clinical reason for delay have a D2B time ?90 minutes.[2] Some centers have implemented protocols and technology to reduce this to much faster times. In addition, with improvements in timeliness of care across the country, racial disparities in reperfusion times have been reduced significantly, the guidleines state.

The guidelines found that for STEMI patients reported by hospitals to the Centers for Medicare and Medicaid Services, median D2B times fell from 96 minutes in the year ending Dec. 31, 2005, to 64 minutes in the three quarters ending Sept. 30, 2010. This decline was accompanied by an increase in the percentage of patients with D2B times <90 minutes, from 44.2 to 91.4 percent. However, despite substantial improvements in D2B times, evidence that these efforts have translated into reduced mortality rates is lacking, the authors found. The absence of demonstrated benefit may relate to reduced power to show change in survival in a population with a relatively low mortality rate, improved early survival of higher-risk patients and changing STEMI demographics.  The guideline authors said these findings support the goal of comprehensive efforts to improve all aspects of acute myocardial infaction care to improve survival rates.

To read more on how to lower door-to-balloon times, read the story linked here.

 

References:

1. Gregory Dehmer, Douglas Weaver, Matthew T. Roe, et al. “A Contemporary View of Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention in the United States: A Report From the CathPCI Registry of the National Cardiovascular Data Registry, 2010 Through June 2011.” J Am Coll Cardiol. 2012;60(20): 2017-2031.

2. Patrick O’Gara, Fredrick Kushner, Deborah Ascheim, et al. “2013 ACCF/AHA Guideline for Management of ST-Elevation Myocardial Infarction.” JACC Vol. 61, No. 4, Jan. 2013.

Related Content

Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Sponsored Content | Videos | Inventory Management| February 17, 2017
The supplies you use in your cath lab are complex and very valuable.
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain
News | CT Angiography (CTA)| February 14, 2017
The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Overlay Init